Head-to-head · Value Score
Gimme Care vs Zealthy
Two GLP-1 deals, scored on the same six factors. Gimme Care lands a Value Score of 91, Zealthy a 54. Here's who gives you the honest lower price — and where each one bites back.
Gimme Care
#5 · Grade A · Best Value
Est. first month
$130/mo
Save ~90% vs brand-nameZealthy
#382 · Grade C · Watch List
Est. first month
From $286/mo (starting dose, plus a separate fee, compounded)
Save ~79% vs brand-nameThe verdict
Gimme Care takes it on Value Score, 91 to 54 — an est. $130/mo first month, with no teaser step-up baked in. Zealthy isn't out of it: Shoppers who want not currently recommended — listed for transparency and reader awareness only.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Gimme Care | Zealthy |
|---|---|---|
| Value Score | 91 (A) | 54 (C) |
| Est. first month | $130/mo | From $286/mo (starting dose, plus a separate fee, compounded) |
| Save vs brand-name | ~90% | ~79% |
| Semaglutide | $130/mo | From $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $163/mo | From $351/mo (starting dose, plus a separate fee, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | 34 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Gimme Care
Genuinely cheap on both molecules ($130 / $163) with a LegitScript-certified pharmacy and all-50-state reach.
Why it's a deal
- Low flat price on both molecules ($130 sema / $163 tirz)
- LegitScript-certified pharmacy
- Available in all 50 states
The fine print
- No brand-name option — compounded only
- No oral/sublingual form
Zealthy
Zealthy (legal entity FitRX, LLC, recently renamed to Gronk Inc.) offers compounded semaglutide and tirzepatide via an asynchronous telehealth model.
Why it's a deal
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
The fine print
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Gimme Care is ranked on the Gimme Care alternatives board, and the same list for the other side is on alternatives to Zealthy.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.